Sigma-Aldrich has announced the commercialization of the TargeTron Gene Knockout System. TargeTron provides a robust and simple method for site-specific disruption of DNA sequences within a host cell genome, Sigma-Aldrich said. The technology exploits the retrohoming ability of group II introns in order to “target” the exact position of gene disruption, the company said. The technology was developed by Alan Lambowitz from the University of Texas at Austin, and licensed from Ingex, Sigma-Aldrich said.
Celliance, a wholly owned subsidiary of Serologicals, has announced the introduction of Hybri-CYTE, a serum-free cell culture supplement designed and optimized for use in hybridoma cell culture. The supplement has been proven to work with mouse-, rat-, and rabbit-derived cell lines, Celliance said.
Peakdale Molecular has launched its fourth Peakexplorer GPCR library, featuring more than 1,100 compounds specifically designed, synthesized, and characterized for screening against GPCR targets. This latest library has been created through the assessment of seven chemotypes intended to target GPCRs, Peakdale said.